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Abstract 
Background: SLC10A4 belongs to the solute carrier family SLC10 whose founding members are the Na+/tauro-
cholate co-transporting polypeptide (NTCP, SLC10A1) and the apical sodium-dependent bile acid transporter (ASBT, 
SLC10A2). These carriers maintain the enterohepatic circulation of bile acids between the liver and the gut. SLC10A4 
was identified as a novel member of the SLC10 carrier family with the highest phylogenetic relationship to NTCP. The 
SLC10A4 protein was detected in synaptic vesicles of cholinergic and monoaminergic neurons of the peripheral and 
central nervous system, suggesting a transport function for any kind of neurotransmitter. Therefore, in the present 
study, we performed systematic transport screenings for SLC10A4 and also aimed to identify the vesicular sorting 
domain of the SLC10A4 protein.
Results: We detected a vesicle-like expression pattern of the SLC10A4 protein in the neuronal cell lines SH-SY5Y and 
CAD. Differentiation of these cells to the neuronal phenotype altered neither SLC10A4 gene expression nor its vesicu-
lar expression pattern. Functional transport studies with different neurotransmitters, bile acids and steroid sulfates 
were performed in SLC10A4-transfected HEK293 cells, SLC10A4-transfected CAD cells and in Xenopus laevis oocytes. 
For these studies, transport by the dopamine transporter DAT, the serotonin transporter SERT, the choline transporter 
CHT1, the vesicular monoamine transporter VMAT2, the organic cation transporter Oct1, and NTCP were used as posi-
tive control. SLC10A4 failed to show transport activity for dopamine, serotonin, norepinephrine, histamine, acetylcho-
line, choline, acetate, aspartate, glutamate, gamma-aminobutyric acid, pregnenolone sulfate, dehydroepiandroster-
one sulfate, estrone-3-sulfate, and adenosine triphosphate, at least in the transport assays used. When the C-terminus 
of SLC10A4 was replaced by the homologous sequence of NTCP, the SLC10A4-NTCP chimeric protein revealed clear 
plasma membrane expression in CAD and HEK293 cells. But this chimera also did not show any transport activity, 
even when the N-terminal domain of SLC10A4 was deleted by mutagenesis.
Conclusions: Although different kinds of assays were used to screen for transport function, SLC10A4 failed to show 
transport activity for a series of neurotransmitters and neuromodulators, indicating that SLC10A4 does not seem to 
represent a typical neurotransmitter transporter such as DAT, SERT, CHT1 or VMAT2.
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Background
The orphan carrier SLC10A4 belongs to the solute carrier 
family SLC10, whose founding members are the Na+/tau-
rocholate co-transporting polypeptide NTCP (SLC10A1) 
and the apical sodium-dependent bile acid transporter 
ASBT (SLC10A2) [1]. These carriers maintain the enter-
ohepatic circulation of bile acids by sodium-dependent 
bile acid reabsorption in the gut via ASBT and sodium-
dependent bile acid transport into hepatocytes via NTCP 
[2]. A further member of this carrier family, the sodium-
dependent organic anion transporter SOAT (SLC10A6), 
is expressed in spermatocytes in man and mouse and 
has transport activity for sulfo-conjugated steroid hor-
mones [3–5]. The other members of this carrier family, 
SLC10A3, SLC10A4, SLC10A5, and SLC10A7, have been 
characterized at the molecular and expression level, but 
still remain orphan carriers [1, 6–12].
The SLC10A4 transcript was first cloned from rat in our 
group in 2004 and showed predominant expression in the 
central nervous system in man, rat, and mouse [13]. Fur-
ther expression analyses on the protein level localized 
SLC10A4 to cholinergic and monoaminergic neurons of 
the central and peripheral nervous system as well as to 
mast cells [13–15]. In contrast to NTCP, ASBT, and SOAT, 
the SLC10A4 protein is not directed to the plasma mem-
brane, but typically showed a vesicular expression pattern 
in neuronal cells, mast cells, and even in transiently or sta-
bly transfected cells lines [6, 13–15]. Based on this expres-
sion pattern, it was assumed that SLC10A4 may represent a 
novel vesicular carrier for any kind of neurotransmitter or 
neuromodulator [1, 6, 13–15]. More recently, in a series of 
very elegant experiments on Slc10a4 knockout mice it was 
shown by the Kullander group that these mice are hyper-
sensitive to the psychostimulants amphetamine and tra-
nylcypromine, and have an altered response to cholinergic 
stimuli at the neuromuscular junction and in the central 
cholinergic system, suggesting that SLC10A4 may contrib-
ute to the vesicular storage or release of neurotransmitters 
[15–17]. Therefore, in the present study, we performed sys-
tematic transport screenings for SLC10A4 in transfected 
neuronal and HEK293 cell lines as well as in Xenopus lae-
vis oocytes and also aimed to identify the vesicular sorting 
domain of the SLC10A4 protein. Although we have not 
identified a transported substrate for SLC10A4 to date, 
recent descriptions of taurocholic acid and lithocholic acid 
transport by a thrombin-modified variant of SLC10A4 [18] 
encouraged us to present our data to provide a broader 
basis for further SLC10A4 transport studies.
Results
Endogenous expression of SLC10A4 in neuronal cell lines
The primary goal of the present study was to identify a 
transported substrate for the orphan carrier SLC10A4 
with an in vitro approach. As the endogenous expression 
of SLC10A4 is exclusively directed to neuronal cells and 
mast cells [13, 14], neuronal cell cultures were thought to 
be the most appropriate for this purpose. Therefore, we 
analyzed SLC10A4 expression in the human neuroblas-
toma cell line SH-SY5Y as well as in the mouse cell line 
CAD (Cath.a-differentiated neuronal cells, originating 
from the locus coeruleus in the brainstem) with different 
SLC10A4-directed antibodies.
SH-SY5Y cells showed a typical neuroblast-like appear-
ance with small, round cell bodies and occasional short 
extensions. Under incubation with retinoic acid (RA) 
and the neurotropic factors tumor growth factor beta 
(TGF-β1) and bone morphogenetic protein 2 (BMP-2), 
the cells stopped proliferation and developed neurite-like 
long extensions, as described previously [19, 20]. Under 
both conditions, SLC10A4 showed a clear vesicle-like 
expression pattern in the SH-SY5Y cells and was detect-
able even along the long neurite-like outgrowths, indi-
cating sorting of the SLC10A4 protein to the synaptic 
direction of the differentiated SH-SY5Y cells (Figure 1b). 
At the RNA level, SLC10A4 showed an overall higher 
expression in the SH-SY5Y cells compared with vesicu-
lar acetylcholine transporter (VAChT) and vesicular 
monoamine transporter 2 (VMAT2) (data not shown), 
but incubation with TGF-β1 + RA or BMP-2 + RA did 
not significantly affect the SLC10A4 mRNA expression 
levels, indicating that SLC10A4 expression is not regu-
lated by the RA, BMP-2, or TGF-β1 triggered signaling 
cascades (Figure  1a). Although transient transfection of 
SLC10A4 into SH-SY5Y revealed an identical expression 
pattern compared with the endogenous expression, as 
shown for an SLC10A4-RFP construct in Figure  1c, the 
transfection rate of these cells could not be enhanced 
above 20% by different transfection methods (lipofection, 
non-liposomal transfection, electroporation), meaning 
that SH-SY5Y cells overexpressing SLC10A4 vs. non-
transfected SH-SY5Y cells could not be used for trans-
port studies. For the same reason, down-regulation of 
SLC10A4 expression by transfection of SLC10A4 siRNA 
prior to transport experiments was also not considered.
Similar to the SH-SY5Y cells, the SLC10A4 protein 
was detected in vesicular structures in mouse CAD cells. 
These cells were differentiated to a neuronal phenotype by 
serum depletion, as previously reported [21]. As shown in 
Figure 1e, under these conditions, long neurite-like exten-
sions were formed which were highly immunoreactive for 
the anti-Slc10a4 antibody. However, even in these cells, 
RNA expression of SLC10A4 was not significantly affected 
by neuronal differentiation (Figure  1d). Although CAD 
cells could easily be transfected with different SLC10A4 
constructs with transfection rates above 80%, these cells 
significantly detached after the transfection procedure 
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and then could not be further subjected to standard trans-
port assays. Therefore, overexpression of SLC10A4 or 
down-expression by RNAi transfection of these cells was 
not practicable for transport screening assays.
Localization of the SLC10A4 protein in the central and 
peripheral nervous system of the rat, as well as in rat PC12 
cells [13, 14], human SH-SY5Y cells, and mouse CAD 
cells (present study), was performed by us with a self-
generated polyclonal rabbit antibody—1338 C—directed 
against the amino acid residues 422–437 (VGTDDLVL-
METTQTSL) of the deduced rat Slc10a4 protein sequence 
[GenBank:AAV80706]. In order to further verify SLC10A4 
expression in neuronal cell cultures with different antibod-
ies, we screened mouse CAD cells by immunofluorescence 
and Western blot analysis, and found by all of the used 
antibodies—directed against the 324–437 amino acids 
of the C-terminus of human SLC10A4 protein (Sigma 
Prestige rabbit anti-SLC10A4), the 1–27 amino acids of the 
N-terminus of mouse and rat SLC10A4 protein (Abnova 
rabbit anti-Slc10a4), and the 377–406 amino acids of the 
C-terminus of the human SLC10A4 protein (Abgent rab-
bit anti-SLC10A4)—a clear vesicle-like expression pat-
tern. The mouse SLC10A4 protein consistently showed an 
apparent molecular weight of 30–32 kDa in the Western 
blot (Figure  1f). This is below the calculated molecular 
weight of 47 kDa, which has been reported for other mem-
bers of the SLC10 carrier family as well [8].
In vitro transport studies on SLC10A4 with candidate 
substrates
As these neuronal cell lines were difficult to handle for 
standard transport experiments, we decided to use trans-
fected human embryonic kidney (HEK) 293 cells as well as 
SLC10A4 cRNA injected X. laevis oocytes, which are both 
Figure 1 Expression and subcellular localization of SLC10A4 in SH-SY5Y and CAD cells. a Relative SLC10A4 gene expression in SH-SY5Y cells after 
differentiation with TGF-ß1 + RA or BMP-2 + RA. Values represent mean ± SD of triplicate measurements. b Immunofluorescence analysis of 
the subcellular expression of the SLC10A4 protein in SH-SY5Y cells. Cells were either untreated (UD), or were differentiated with TGF-ß1 + RA or 
BMP-2 + RA over 4 days prior to immunolabeling. The SLC10A4 protein was detected with the anti-Slc10a4 1338 C antibody (1:1,000) and the Cy3-
labelled anti-rabbit secondary antibody (1:800, red fluorescence) and nuclei were stained with DAPI (blue fluorescence). In all cases, the SLC10A4 
protein showed a vesicle-like expression pattern within the perikarya and along the neurite-like cellular protrusions. c Even when a fluorescence-
tagged SLC10A4-RFP construct was transiently transfected into SH-SY5Y cells, the SLC10A4-RFP protein showed a clear vesicular sorting pattern.  
d Relative Slc10a4 gene expression analysis in differentiated (Diff ) and undifferentiated (UD) CAD cells. The values represent mean ± SD of triplicate 
measurements. e Endogenous expression of the SLC10A4 protein in CAD cells, cultivated in FCS containing medium (UD) or FCS-free medium 
(Diff ). The SLC10A4 protein was detected with the anti-Slc10a4 1338 C antibody (1:500) and the Cy3-labelled secondary antibody (1:800, red fluo-
rescence). For control, the primary anti-Slc10a4 antibody was omitted (control) or the antibody was pre-incubated with the immunizing peptide 
(peptide blocking). f Immunofluorescence detection of the SLC10A4 protein was performed with different SLC10A4-directed antibodies (green 
fluorescence): self-generated polyclonal rabbit anti-Slc10a4 1338 C antibody, rabbit anti-SLC10A4 Sigma Prestige antibody, rabbit anti-Slc10a4 
Abnova antibody, and rabbit anti-SLC10A4 Abgent antibody. Membrane protein enriched fractions of the CAD cells were also subjected to Western 
Blot analysis with the same antibodies and revealed specific bands for the SLC10A4 protein at an apparent molecular weight of 30–32 kDa.
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well-established in vitro cell models for transport measure-
ments [3, 22]. We previously reported that, apart from its 
predominant intracellular expression, the SLC10A4 pro-
tein can to a lower extent also be detected in the plasma 
membrane of transfected HEK293 cells [13]. Therefore, 
we first used HEK293 cells transiently transfected with the 
human SLC10A4 construct for classical uptake measure-
ment in intact cells. As positive controls, the plasma mem-
brane neurotransmitter transporters dopamine transporter 
(DAT), choline transporter (CHT1), and serotonin trans-
porter (SERT) were also transfected, and empty-vector 
transfected cells served as negative controls. Whereas DAT 
showed a significant nomifensine-sensitive and sodium-
dependent uptake of [3H]dopamine, SLC10A4-transfected 
HEK293 cells tended to accumulate more dopamine com-
pared with the control, but without reaching a level of sig-
nificance (Figure 2). SLC10A4 showed no transport activity 
for [3H]norepinephrine, [3H]serotonin and [3H]choline 
at all, whereas DAT, SERT and CHT1 significantly trans-
ported their substrates in a sodium-dependent manner.
In our previous study, we reported co-expression of the 
SLC10A4 protein with VMAT2 in synaptic vesicles of 
rat brain preparations [14], so we next intended to ana-
lyze the SLC10A4 transport in direct comparison with 
VMAT2. In this approach, we used HEK293 cells stably 
transfected with human SLC10A4 or human VMAT2, 
which were permeabilized with digitonin in order to 
facilitate access of the transport substrate to the site of 
carrier expression in intracellular vesicular structures, 
as described before [23]. As shown in Figure 3, VMAT2 
showed significant transport activity for [3H]seroto-
nin, [3H]norepinephrine, and [3H]dopamine which was 
dependent on the presence of adenosine triphosphate 
(ATP) in the transport buffer as well as sensitive to tetra-
benazin (TBZ) and carbonylcyanide-p-trifluoromethoxy-
phenylhydrazon (FCCP). However, in contrast, SLC10A4 
showed no transport activity for serotonin, norepi-
nephrine, and dopamine at all in this vesicular trans-
port assay. We also could not demonstrate a transport 
of acetylcholine, neither for SLC10A4 nor for VAChT 
Figure 2 Transport measurements in transiently transfected HEK293 cells. HEK293 cells were transiently transfected with the indicated carriers 
SLC10A4, DAT, CHT1, or SERT, respectively. The uptake of 5 µM [3H]dopamine, 5 µM [3H]norepinephrine, 5 µM [3H]choline, or 5 µM [3H]serotonin was 
measured over the given time periods in the presence and absence of Na+ (for CHT1 Na+ was replaced by Li+). Transport via DAT, CHT1, and SERT 
was blocked by the specific inhibitors nomifensine (10 µM), hemicholinium-3 (HC-3, 1 µM), and citalopram (2 µM), respectively. Values represent 
mean ± SD of representative experiments, each with quadruplicate determinations (n = 4). *Significantly different from control with p < 0.001. 
#Significantly different from positive uptake, p < 0.001.
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in permeabilized HEK293 cell lines transfected with the 
respective construct (data not shown).
In previous studies at our institute we learned that the 
transport rates for a particular carrier may be higher in 
the X. laevis oocytes expression system compared with 
transfected cell cultures. Furthermore, we demonstrated 
in a previous study that at least the rat SLC10A4 protein 
is expressed at the plasma membrane of X. laevis oocytes 
[13]. Therefore, we injected SLC10A4 cRNA in X. laevis 
oocytes and screened for transport activity with a series 
of neurotransmitters and further SLC10A4 candidate 
substrates. For these experiments, water-injected oocytes 
served as negative control and, if appropriate, oocytes 
injected with cRNA coding for SERT, DAT, NTCP, or 
mouse organic cation transporter 1 (Oct1) were used as 
positive controls. As shown in Figure 4, SERT, DAT, and 
Oct1 showed significant transport activity for seroto-
nin, dopamine, and histamine, respectively, but SLC10A4 
cRNA injected oocytes were not different from the con-
trol. Furthermore, the neurosteroids pregnenolone sulfate 
(PREGS) and dehydroepiandrosterone sulfate (DHEAS) as 
well as the bile acid taurocholic acid, were not transported 
by SLC10A4 in this transport assay, although NTCP 
showed significant transport activity for all of them. Apart 
from these candidate substrates, SLC10A4 also showed no 
transport activity for aspartate, acetate, choline, gamma-
aminobutyric acid (GABA), norepinephrine, glutamate, 
acetylcholine, estrone-3-sulfate (E-3-S), lithocholic acid, 
and ATP in the X. laevis oocytes model (Table 1).
Very recently, it was reported that the N-terminal 
domain of the SLC10A4 protein could be cleaved by 
thrombin treatment and thereby transport activity for 
taurocholic acid and lithocholic acid may be activated 
[18]. Although these data were obtained in a neuronal cell 
culture of TE671 cells, in the present study, we intended 
to reproduce these data on the isolated over-expressed 
SLC10A4 protein and used HEK293 cells stably trans-
fected with SLC10A4 as well as with NTCP for the con-
trol. Both, SLC10A4-HEK293 and NTCP-HEK293 cell 
lines were treated with 1 U/200  µl of thrombin for 3  h 
prior to transport measurements with [3H]DHEAS, [3H]
taurocholic acid, [3H]PREGS, and [3H]lithocholic acid. 
As expected, NTCP showed significant transport activ-
ity for DHEAS, taurocholic acid and PREGS, and was not 
affected by thrombin treatment. In contrast, SLC10A4 
did not transport any of these compounds, even after 
pre-treatment with thrombin (Figure  5). No transport 
activity could be observed for lithocholic acid at all, nei-
ther in NTCP nor in the SLC10A4-expressing HEK293 
cells. Therefore, transport activity of SLC10A4 could not 
be activated by thrombin treatment in the cell model 
used.
Localization of the vesicular sorting domain in the 
C‑terminus of SLC10A4
A further aim of the present study was to localize the 
particular domain of SLC10A4 that is responsible for 
the vesicular sorting of this protein. This question was 
of particular interest, as mutation of this domain might 
redirect the SLC10A4 protein to the plasma mem-
brane, which would facilitate further substrate screen-
ing. As within the SLC10 carrier family, NTCP, which is 
Figure 3 Transport measurements in digitonin permeabilized SLC10A4-HEK293 and VMAT2-HEK293 cells. Prior to transport measurements, stably 
transfected human SLC10A4-HEK293 cells and human VMAT2-HEK293 cells were pre-incubated with 15 µM digitonin for 10 min for permeabiliza-
tion. Then the uptake of 400 nM [3H]serotonin, [3H]norepinephrine, or [3H]dopamine was measured over 10 min in the presence and absence 
of 5 mM ATP in the transport buffer. In addition to ATP, 2 µM of the potent VMAT2 inhibitor tetrabenazine (TBZ) or 5 µM of the proton ionophore 
carbonylcyanide-p-trifluoromethoxyphenylhydrazon (FCCP) were added to the transport buffer as indicated. After 10 min, the cells were washed 
with ice-cold PBS, lysed, and subjected to scintillation counting. The values represent mean ± SD of one representative experiment (for dopamine, 
n = 4) or two independent experiments (for serotonin and norepinephrine, n = 8). *Significantly different from control with p < 0.05. #Significantly 
different from positive uptake, p < 0.05.
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expressed at the plasma membrane, is the most related 
carrier to SLC10A4, we generated several SLC10A4/
NTCP chimeric constructs in which the C-terminal 
and N-terminal domains were interchanged between 
both carriers (Figure  6a). Furthermore, we generated a 
75ΔSLC10A4 mutant which was truncated by the first 
75  N-terminal amino acids. All constructs were trans-
fected in neuronal CAD cells as well as in HEK293 cells 
and used for immunofluorescence analysis of protein 
localization (Figure  6b) as well as for transport experi-
ments with SLC10A4 candidate substrates (Figure  6c; 
Table  2). As shown in Figure  6b, NTCP showed clear 
plasma membrane localization in CAD cells, whereas 
SLC10A4 showed expression in intracellular vesicles. 
Interestingly, both chimeras bearing the C-terminus of 
NTCP (i.e. SLC10A4-CtNTCP and NtNTCP-SLC10A4-
CtNCTP) were detected at the plasma membrane, 
whereas all chimeric proteins with the C-terminus of 
SLC10A4 (i.e. NTCP-CtSLC10A4, NtSLC10A4-NTCP-
CtSLC10A4) were detected in intracellular vesicles. This 
sorting pattern was basically the same when these con-
structs were transfected and analyzed in HEK293 cells 
(data not shown). This indicates that the C-termini of 
NTCP and SLC10A4 are dominant for the sorting to 
the plasma membrane and intracellular vesicles, respec-
tively. In contrast, truncation of the SLC10A4  N-ter-
minus (75ΔSLC10A4 mutant) as well as transfer of the 
SLC10A4  N-terminus into the NTCP (NtSLC10A4-
NTCP chimera) did not affect the sorting of SLC10A4 
Figure 4 Transport measurements in Xenopus laevis oocytes. 
Xenopus laevis oocytes were injected with cRNA coding for human 
SLC10A4, SERT, DAT, or NTCP as well as mouse Oct1. Uptake of [3H]
serotonin, [3H]histamine, [3H]PREGS, [3H]dopamine, [3H]DHEAS, or 
[3H]taurocholic acid, each at 1 µM, was measured over a time period 
of 10–60 min as indicated in the presence of sodium chloride in the 
transport buffer. SERT, Oct1, and DAT served as controls for the trans-
port of [3H]serotonin, [3H]histamine, and [3H]dopamine, respectively. 
NTCP was the reference carrier for PREGS, DHEAS and taurocholic 
acid. Afterwards, the oocytes were washed with ice-cold transport 
buffer, lysed and subjected to scintillation counting. The values 
represent mean ± SD of one representative experiment with n = 10 
oocytes each. *Significantly different from control with p < 0.001.
Table 1 Transport studies in Xenopus laevis oocytes
Xenopus laevis oocytes were injected with human SLC10A4 cRNA or with water 
(control). Values represent uptake of the indicated compound as mean  ±  SD 
of at least 10 oocytes per group. Ratio represents uptake into SLC10A4 cRNA-
injected oocytes divided by uptake into water-injected oocytes.
SLC10A4 Control Ratio
Uptake (pmol/oocyte/60 min)
[3H]Histamine (10 µM) 0.29 ± 0.02 0.27 ± 0.01 1.0
[3H]Aspartate (1 µM) 0.22 ± 0.01 0.28 ± 0.01 0.8
[3H]Acetate (25 µM) 8.79 ± 0.51 8.36 ± 0.72 1.0
[3H]Choline (1 µM) 2.68 ± 0.52 2.20 ± 0.19 1.2
[3H]GABA (1 µM) 0.52 ± 0.05 0.47 ± 0.04 1.1
[3H]Norepinephrine (1 µM) 0.16 ± 0.01 0.21 ± 0.02 0.8
[3H]Glutamate (1 µM) 0.014 ± 0.001 0.014 ± 0.002 1.0
Uptake (pmol/oocyte/30 min)
[3H]Acetylcholine (10 µM) 43.51 ± 3.62 37.51 ± 3.67 1.2
[3H]Dopamine (10 µM) 1.36 ± 0.06 1.43 ± 0.05 1.0
[3H]PREGS (1 µM) 1.19 ± 0.09 1.06 ± 0.09 1.1
[3H]DHEAS (1 µM) 0.043 ± 0.002 0.043 ± 0.004 1.0
[3H]E-3-S (1 µM) 0.050 ± 0.001 0.060 ± 0.005 0.8
Uptake (pmol/oocyte/10 min)
[3H]Lithocholic acid (0.3 µM) 3.68 ± 0.23 4.13 ± 0.07 0.9
[3H]Taurocholic acid (0.3 µM) 0.0158 ± 0.0009 0.0159 ± 0.0007 1.0
[3H]ATP (5 mM) 70.66 ± 9.06 68.84 ± 8.26 1.0
[35S]Adenosine 5`-(γ-thio) 
triphosphate (5 mM)
69.76 ± 4.36 67.73 ± 2.53 1.0
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and NTCP, respectively, indicating that the C-terminus, 
but not the N-terminus of the SLC10A4 protein is rel-
evant for the protein sorting. Apart from localizing 
the sorting domains in the SLC10A4 protein, several 
of the constructs were of particular interest for trans-
port experiments. (I) When the N-terminal domain 
of SLC10A4, which was previously supposed to hin-
der substrate binding to the SLC10A4 carrier protein 
[18], were transferred to the NTCP in order to produce 
a NtSLC10A4-NTCP elongated chimera, the trans-
port function for taurocholic acid remained completely 
intact compared with wild-type NTCP (Figure  6c). (II) 
Furthermore, activation of the SLC10A4-mediated tau-
rocholic acid transport by thrombin cleavage of the 
N-terminus was supposed [18]. However, for the N-ter-
minally truncated 75ΔSLC10A4 protein, as well as for 
the NtNTCP-SLC10A4-CtNTCP chimera, still no trans-
port activity for taurocholic acid could be observed. (III) 
Just by replacing the SLC10A4 C-terminal 63 amino 
acids by the corresponding C-terminus of NTCP in the 
SLC10A4-CtNTCP and NtNTCP-SLC10A4-CtNTCP 
chimera, the SLC10A4 protein was directed to the 
plasma membrane. Therefore, these chimeras represent 
an interesting tool for SLC10A4 substrate screening. As 
the CAD cells detached after transfection of the respec-
tive constructs when they were further processed for the 
routine transport assay, the radiolabelled candidate sub-
strates were added directly into the cell culture medium 
and cell associated radioactivity was analyzed. However, 
neither SLC10A4-CtNTCP nor NtNTCP-SLC10A4-
CtNTCP showed transport activity so far for taurocholic 
acid and serotonin (Figure  6c) as well as for DHEAS, 
PREGS, E-3-S, dopamine, glutamate, histamine, acetyl-
choline, and choline (Table 2).
Discussion
SLC10A4 is a member of the SLC10 carrier family com-
monly referred to as the “family of sodium-dependent 
bile acid transporters”. The rat Slc10a4 transcript was 
first cloned in our group in 2004 [GenBank:AY825923] 
[13] and the human SLC10A4 sequence was published 
in 2006 [6]. The SLC10A4 protein consists of 437 amino 
acids in man, rat, and mouse, and shows a close phylo-
genetic relationship to the sodium-dependent bile acid 
transporter NTCP. However, whereas NTCP is specifi-
cally expressed at the sinusoidal plasma membrane of 
hepatocytes [2], the SLC10A4 protein was localized in 
cholinergic and monoaminergic neurons of the central 
and peripheral nervous system as well as in pheochro-
mocytoma PC12 cells and mast cells [13–15]. Based on 
its genetic classification, SLC10A4 first was suggested to 
be a novel carrier for already established substrates of the 
SLC10 carrier family, including bile acids and sulfo-con-
jugated steroid hormones [1, 6, 13]. However, based on 
its expression pattern, it seems more likely that SLC10A4 
plays a role for the vesicular storage or exocytosis of any 
kind of neurotransmitter or mediator in neurons and 
mast cells [14]. In previous experiments, the neuroster-
oids PREGS and DHEAS were already considered to be 
particularly promising candidate substrates. These neu-
rosteroids can modulate several postsynaptic receptor 
systems and even interfere with the release of multiple 
neurotransmitters including acetylcholine, norepineph-
rine, dopamine and serotonin [24–26]. However, until 
now, all transport measurements performed with E-3-S, 
DHEAS, and PREGS have so far failed to show transport 
function for SLC10A4 [6, 13] (present study). However, a 
more systematic transport screening also including clas-
sical neurotransmitters as candidate substrates has not 
Figure 5 Transport measurements in stably transfected SLC10A4-HEK293 and NTCP-HEK293 cells after thrombin treatment. For the transport 
measurements, one part of the cells was pre-incubated with 1 U/200 µl thrombin over 3 h (+Thrombin), before the uptake of [3H]DHEAS, [3H]
taurocholic acid, [3H]PREGS, or [3H]lithocholic acid (each at 300 nM) was measured over a time period of 10 min at 37°C. The cells were washed with 
ice-cold PBS, lysed, and subjected to scintillation counting. The values represent mean ± SD of two independent experiments each with triplicate 
determinations. *Significantly different from control with p < 0.001; n.s. not significantly different.
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yet been performed. Therefore, in the present study, we 
aimed to screen for SLC10A4 transport function with 
different transport assays, including transport in intact 
HEK293 cells and neuronal CAD cells, permeabilized 
HEK293 cells and X. laevis oocytes. Overall, no trans-
port activity for SLC10A4 was found for taurocholic 
acid, lithocholic acid, DHEAS, PREGS, E-3-S, acetylcho-
line, choline, acetate, glutamate, aspartate, GABA, ATP, 
serotonin, histamine, dopamine, and norepinephrine in 
the respective transport assay. Although we used differ-
ent kinds of transport assays and cell models, it might be 
the case that SLC10A4 has transport function for one of 
the mentioned compounds anyway. In HEK293 cells and 
X. laevis oocytes, an additional factor might have been 
missed that is only present in neuronal cells. However, 
overexpression of the SLC10A4 protein or permeabi-
lization of the cells prior to transport experiments was 
not practicable in neuronal cell lines as the cells either 
showed low transfection rates (as the SH-SY5Y cells) or 
promptly detached when the incubation medium was 
repeatedly changed (CAD cells). Furthermore, all trans-
port assays performed in SLC10A4-transfected CAD 
Figure 6 Localization and transport function of SLC10A4/NTCP chimeras in CAD cells. a The shown SLC10A4/NTCP chimeric constructs were used. 
All chimeras were generated based on the full length sequences of SLC10A4 (grey marked transmembrane domains and loops with continuous 
lines) and NTCP (white transmembrane domains and loops as dotted lines), both with c-terminal V5-tag. Potential glycosylation sites were marked 
by “Y”. b All constructs were transiently transfected in CAD cells and cellular localization was analyzed by immunofluorescence microscopy using 
rabbit anti-V5 antibody and donkey Cy3-labelled anti-rabbit secondary antibody. Nuclei were stained with DAPI. Whereas SLC10A4 showed a clear 
vesicle-like expression pattern, the immunofluorescence signals for NTCP, NtSLC10A4-NTCP, SLC10A4-CtNTCP, and NtNTCP-SLC10A4-CtNTCP were 
clearly directed to the plasma membrane. When the 75 N-terminal amino acids were deleted in SLC10A4, the 75ΔSLC10A4 protein retained its 
vesicle-like intracellular expression comparable with full-length SLC10A4. c The SLC10A4/NTCP chimeras were also used for transport studies after 
transient transfection into CAD cells with [3H]taurocholic acid and [3H]serotonin, each at 5 µM. These measurements were performed by incubating 
the cells for 60 min at 37°C in 250 µl cell medium with 50 µl sodium transport buffer containing the radiolabeled and non-radiolabeled compounds. 
NTCP and SERT were used as a positive control, and empty-vector transfected cells served as the negative control. After the uptake phase, cells 
were washed with ice-cold PBS, lysed, and subjected to scintillation counting. Data represent mean ± SD of representative experiments each with 
quadruplicate determinations. *Significantly different from control with p < 0.01.
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cells also failed to show transport activity for SLC10A4. 
Nevertheless, further investigations on the SLC10A4 
transport function should focus on vesicle preparations 
from SLC10A4-deleted neuronal cell cultures or may use 
liposomal reconstitution of the SLC10A4 protein.
Very recently, it was suggested by Abe et  al. [18] that 
SLC10A4 may represent a protease-activated trans-
porter for the bile acids taurocholic acid and lithocholic 
acid. They used the human medulloblastoma cell line 
TE671 in which they localized the SLC10A4 protein by 
immunofluorescence and Western Blot analysis with a 
commercial anti-SLC10A4 antibody and showed that 
pre-incubation of the cells with 1U/200  µl of thrombin 
for 3 h increased the cellular uptake of taurocholic acid 
and lithocholic acid [18]. However, appropriate controls 
demonstrating specificity of the antibody were not pro-
vided and the authors failed to seriously show saturable 
transport kinetics for this uptake. Furthermore, bioin-
formatics analysis (Expasy Peptide Cutter, http://www.
web.expasy.org/peptide_cutter/) indicates that the mouse 
and rat SLC10A4 proteins can be cleaved by thrombin 
at amino acid position 87, but not the human SLC10A4 
protein. Nevertheless, in the present study, these experi-
ments were repeated by using HEK293 cells overexpress-
ing SLC10A4, providing a better controllable system, but 
did not show any transport activity of SLC10A4 for tau-
rocholic acid after treatment with thrombin. Due to these 
negative data and based on the bioinformatics prediction 
we did not further analyze whether the human SLC10A4 
protein can really be cleaved by thrombin in our experi-
mental setup. Furthermore, when the large N-terminus 
of SLC10A4 was deleted by mutagenesis in the NtNTCP-
SLC10A4-CtNTCP and 75ΔSLC10A4 constructs, no 
transport activity for taurocholic acid was detected. 
This is of particular interest, because it was suggested by 
Abe et al. [18] that the N-terminal domain of SLC10A4 
might hinder substrate binding to the protein. This sug-
gestion can not be supported by data from the present 
study. It is already known that thrombin starting from 1 
U/200 µl has a dose-dependent effect on cell viability of 
neuronal cell cultures [27]. Furthermore, it was reported 
that lithocholic acid selectively kills neuroblastoma cells 
by triggering the extrinsic and intrinsic apoptotic death 
pathways via binding to the surface [28]. Therefore, it 
cannot be excluded that the suggested uptake of tauro-
cholic acid and lithocholic acid may just have resulted 
from the combined surface effects of the bile acids and 
thrombin, but not from carrier-mediated uptake into the 
cells via a thrombin-modified SLC10A4 variant.
During the completion of this study, the Kullander 
group published a series of very elegant experiments on 
Slc10a4 knockout mice, which provide further intrigu-
ing indications of the molecular transport function of 
SLC10A4. In the first study by Zelano et  al. [16], they 
analyzed whether the absence of SLC10A4 may have an 
impact on the function of the central cholinergic system. 
Injection of the cholinergic agonist pilocarpin induced 
status epilepticus earlier and more often in the Slc10a4 
knockout mice compared with the wild type mice, sug-
gesting that SLC10A4 may suppress epileptiform activ-
ity. They concluded that absence of the SLC10A4 protein 
results in cholinergic hypersensitivity of the knockout 
mice [16]. In a second study by Patra et al. [17], the role 
of SLC10A4 on the structure and function of the neuro-
muscular junction was analyzed. Although there were no 
abnormalities detectable at the macrostructure level, the 
Slc10a4 knockout mice showed misshapen neuro-mus-
cular junctions with an increased number of isolated ace-
tylcholine receptor clusters and a decreased number of 
endplate branches. Nevertheless, the knockout mice had 
Table 2 Transport studies in HEK293 cells
Values represent uptake in pmol/mg protein/30 min of the indicated compound as mean ± SD of quadruplicate determinations. Ratio represents uptake into carrier-
expressing HEK293 cells divided by uptake into mock-transfected HEK293 cells. * Significantly different from control with p < 0.01.
Compound (5 µM) NTCP SLC10A4 NtNTCP‑SLC10A4‑CtNTCP
Uptake Ratio Uptake Ratio Uptake Ratio
[3H]E-3-S 276.93 ± 29.12 10.1* 35.23 ± 2.01 1.3 27.91 ± 1.38 1.0
[3H]DHEAS 225.12 ± 16.51 6.9* 38.22 ± 0.90 1.2 31.84 ± 1.38 1.0
[3H]PREGS 1,656.09 ± 201.01 4.7* 366.06 ± 22.23 1.0 383.62 ± 17.38 1.0
DAT SLC10A4 NtNTCP‑SLC10A4‑CtNTCP
[3H]Dopamine 1,578.17 ± 107.47 13.2* 128.61 ± 16.60 1.1 157.92 ± 19.11 1.3
[3H]Glutamate 22.60 ± 2.95 1.4 13.57 ± 1.62 0.8
[3H]Histamine 26.24 ± 1.40 1.3 25.68 ± 0.63 1.3
[3H]Acetyl-choline 352.00 ± 38.76 1.0 307.64 ± 31.41 0.9
[3H]Choline 929.53 ± 30.50 1.1 866.83 ± 23.63 1.0
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normal motor behavior. Electrophysiological measure-
ments on nerve-muscle preparations then showed that 
the Slc10a4 knockout mice had decreased spontaneous 
endplate potential amplitudes, which could be explained 
by lower acetylcholine release at the endplates without 
nerve stimulation. On the other hand, after repeated 
stimulation, the Slc10a4 knockout mice revealed an 
enlarged pool of readily releasable vesicles at the neuro-
muscular junction. However, for the interpretation of 
these data, it has to be considered that the knockout mice 
may have altered gene-expression in order to compensate 
for the loss of SLC10A4, as shown by an up-regulation 
of the nicotinic acetylcholine receptor subunits alpha1 
and delta in the Slc10a4 knockout mice. The authors 
came to the conclusion that the loss of SLC10A4 may 
result in reduced vesicular filling with the neurotrans-
mitter acetylcholine at the neuromuscular junction [17]. 
In a further study by Larhammar et al. [15], the Slc10a4 
knockout mice were not different from their wild-type 
littermates in a series of behavior tests, but showed a 
hypoactive phenotype. Furthermore, the Slc10a4 knock-
out mice were hypersensitive to the psychostimulants 
amphetamine and tranylcypromine. In the central nerv-
ous system, the Slc10a4 knockout mice had reduced lev-
els of dopamine, serotonin, norepinephrine and choline. 
Although no evidence for the direct transport of these 
neurotransmitters by SLC10A4 has been provided, syn-
aptic vesicles from transgenic mice overexpressing the 
SLC10A4 protein showed an increased uptake of [3H]
dopamine, which was probably due to higher synaptic 
vesicle acidification. Based on these data, the authors 
speculate that SLC10A4 may transport any hitherto 
unknown organic anion compound, which would allow 
the vesicular accumulation of higher amounts of protons, 
which then would increase the vesicular storage of neu-
rotransmitters [15]. This conclusion is in agreement with 
data from the present study, in which SLC10A4 showed 
no transport activity for a series of neurotransmitters. 
However, even suggested organic anion modulators such 
as ATP or DHEAS were not transported by SLC10A4, 
meaning that the function of SLC10A4 as solute carrier is 
still a matter of speculation.
Based on their findings, the Kullander group suggested 
renaming SLC10A4 as “vesicular aminergic-associated 
transporter” (VAAT). However, as the naming of the 
carriers of the SLC10 carrier family until now has only 
been based on their molecular transport function, i.e. 
Na+/taurocholate co-transporting polypeptide NTCP 
(SLC10A1), apical sodium-dependent bile acid trans-
porter ASBT (SLC10A2), and sodium-dependent organic 
anion transporter SOAT (SLC10A6), we strongly suggest 
not renaming SLC10A4 before its molecular transport 
function has been elucidated.
The outstanding role of SLC10A4 within the SLC10 
family is not only based on its inability to transport bile 
acids or steroid sulfates. In contrast to NTCP, ASBT and 
SOAT, which all are sorted to the plasma membrane, 
SLC10A4 has a typical intracellular vesicle-like expres-
sion pattern in neurons, mast cells and neuronal cell 
lines. This specific expression pattern of SLC10A4 was 
also observed in the present study in untreated and dif-
ferentiated CAD and SH-SY5Y cells. To more closely 
analyze the sorting domains of SLC10A4, a series of 
NTCP/SLC10A4 chimeras were generated and analyzed 
in HEK293 and CAD cells. These experiments clearly 
showed that the cytoplasmic C-terminus of SLC10A4 
must contain dominant signals for its vesicular sorting. 
Previous studies with rat NTCP demonstrated that the 
tyrosine-based sorting motifs YXXØ within its C-ter-
minus (i.e. Y307-E-K-I and Y321-K-A-A) are involved in 
membrane delivery [29]. Although the C-terminus of 
SLC10A4 also contains these potential tyrosine-based 
sorting motifs (Y406-K–K-L und Y419-G-T-V), SLC10A4 is 
obviously not directed to the plasma membrane. In the 
same way, all chimeric constructs with the C-terminus 
of SLC10A4 (i.e. NTCP-CtSLC10A4 and NtSLC10A4-
NTCP-CtSLC10A4) showed a vesicular expression pat-
tern and failed to transport typical NTCP substrates such 
as taurocholic acid and DHEAS. In contrast, both chi-
meras bearing the C-terminus of NTCP (i.e. SLC10A4-
CtNTCP and NtNTCP-SLC10A4-CtNCTP) were 
detected at the plasma membrane. Further mutagenesis 
experiments now have to localize the vesicular sorting 
motifs of SLC10A4 at the amino acid level.
Conclusions
SLC10A4 is expressed in vesicular structures not only 
in neurons of the central and peripheral nervous sys-
tem, but also in neuronal cell lines such as SH-SY5Y and 
CAD. Although different kinds of assays were applied to 
screen for a transport function, SLC10A4 failed to show 
transport activity for dopamine, serotonin, norepineph-
rine, histamine, acetylcholine, choline, acetate, aspar-
tate, glutamate, GABA, PREGS, DHEAS, E-3-S, and ATP, 
indicating that SLC10A4 does not seem to be a typical 
neurotransmitter transporter. When the C-terminus of 
SLC10A4 was replaced by the homologous sequence of 
NTCP, the SLC10A4-CtNTCP chimera revealed clear 
plasma membrane expression in CAD and HEK293 cells. 
Vice versa, the C-terminus of SLC10A4 directed NTCP 
to intracellular vesicles, indicating that the sorting motifs 
of both carriers seem to be localized in the C-terminus. 
Further SLC10A4 transport studies should involve vesi-
cle preparations from SLC10A4-deleted neuronal cell 
cultures or may use liposomal reconstitution of the 
SLC10A4 protein. Until then, the functional properties 
Page 11 of 14Schmidt et al. BMC Neurosci  (2015) 16:35 
of the SLC10A4 orphan carrier protein still remain 
unknown.
Methods
Materials, chemicals, and radiochemicals
All of the chemicals, unless otherwise stated, were from 
Sigma-Aldrich (Taufkirchen, Germany). Citalopram was 
purchased from Biotrend (Cologne, Germany) and col-
lagenase D was from Serva (Heidelberg, Germany). [3H]
DHEAS (70.5  Ci/mmol), [3H]E-3-S (45.6  Ci/mmol), 
[3H]aspartate (11.3  Ci/mmol), [3H]GABA (76.2  Ci/
mmol), [3H]histamine (13.4  Ci/mmol), [3H]choline 
chloride (66.7  Ci/mmol), [3H]norepinephrine (56.6  Ci/
mmol), [3H]serotonin (28.25  Ci/mmol), [3H]dopamine 
(38.7 Ci/mmol), [3H]glutamate (49.6 Ci/mmol), [3H]ATP 
(30.9  Ci/mmol), [35S]Adenosine 5′-(γ-thio) triphosphate 
(12.5 mCi/mmol) and [3H]acetylcholine iodide (99.7 Ci/
mmol) were purchased from PerkinElmer Life Sciences 
(Boston, MA, USA). [3H]PREGS (20  Ci/mmol), [3H]
taurocholic acid (10.0  Ci/mmol), [3H]acetate (150  mCi/
mmol), and [3H]lithocholic acid (50  Ci/mmol) were 
obtained from American Radiolabeled Chemicals (St. 
Louis, MO, USA).
Culture and differentiation of neuronal cell lines
Human neuroblastoma SH-SY5Y cells (obtained from 
DSMZ Braunschweig, Germany) were maintained at 
37°C in RPMI medium (Gibco, Karlsruhe, Germany) con-
taining 10% fetal calf serum (FCS, Sigma-Aldrich) and 1% 
penicillin/streptomycin (P/S, containing 100 U/ml peni-
cillin and 100  mg/ml streptomycin). For differentiation, 
the cultures at an approximate confluence of 40% were 
placed in serum-free RPMI medium supplemented with 
either 10 µM all-trans RA (Sigma-Aldrich) plus 10 ng/ml 
BMP-2 (BioCat, Heidelberg, Germany) or 10 ng/ml TGF-
β1 (Invitrogen, Karlsruhe, Germany) and were grown 
for 5 days. As a control, cells were grown in serum-free 
RPMI medium without any supplements. Mouse cat-
echolaminergic CAD cells (obtained from European 
Collection of Cell Cultures ECACC, Health Protection 
Agency, UK) were maintained at 37°C in Dulbecco’s 
modified Eagle’s/Ham’s F-12 (1:1) medium (DMEM/F12) 
containing 8% FCS, 4  mM  l-glutamine and 1% P/S at 
37°C. For cell differentiation, 4 ×  105 cells were seeded 
in 6-well or 24-well plates on poly-l-lysine-coated glass 
coverslips and grown in serum-free medium for 24-72 h. 
Under these conditions, the cultures stopped proliferat-
ing and large neurite-like cell extensions appeared.
Immunofluorescence analysis of SH‑SY5Y, CAD, 
and HEK293 cells
For immunofluorescence analysis, SH-SY5Y, CAD, and 
HEK293 cells were seeded at a density of 5 ×  104 cells 
per cm2 in 24-well plates on poly-l-lysine-coated glass 
coverslips and cultured to a confluence of approxi-
mately 40%. For immunofluorescence experiments, 
the cells were washed with phosphate buffered saline 
(PBS, containing 137  mM NaCl, 2.7  mM KCl, 1.5  mM 
KH2PO4, and 7.3  mM Na2HPO4, at pH 7.4) and fixed 
with 2% paraformaldehyde (PFA, Roth, Karlsruhe, Ger-
many) in PBS for 15  min at 4°C. Then, cells were again 
washed with PBS and incubated with 20 mM glycine in 
PBS for 5  min. For permeabilization, cells were incu-
bated for 5 min with PBT buffer (0.2% Triton X-100 and 
20  mM Glycine in PBS). The non-specific binding sites 
were blocked with 1% bovine serum albumin (BSA) plus 
4% goat serum (Sigma-Aldrich) in PBS for 30  min at 
room temperature. Then, the cells were incubated with 
the primary antibodies, rabbit anti-Slc10a4 (antibody 
1338 C, 1:1,000 dilution, see [13, 14] ), Sigma Prestige 
rabbit anti-SLC10A4 (1:500 dilution) [Sigma-Aldrich 
Cat# HPA028835 RRID:AB_10603025], Abnova rab-
bit anti-Slc10a4 (1:500 dilution) [Abnova Corporation 
Cat# PAB14855 RRID:AB_10696081], or Abgent rabbit 
anti-SLC10A4 (1:500 dilution) [Abgent Cat# AP10250b 
RRID:AB_10821224], or with mouse anti-V5 monoclo-
nal antibody (1:5,000 dilution) [Invitrogen Cat# R96025 
RRID:AB_159313] in blocking solution overnight at 4°C. 
The next day, cells were washed with PBS and incubated 
with the fluorophore-labeled secondary antibody Cy3-
conjugated goat anti-rabbit IgG (1:800 dilution) [Jackson 
ImmunoResearch Cat# 111-165-003 RRID:AB_2338000] 
or Alexa fluor 488-labelled goat-anti mouse (1:800 dilu-
tion) [Molecular Probes (Invitrogen) Cat# A11001 
RRID:AB_141367] in blocking solution for 60  min at 
room temperature. After several washing steps with PBS, 
the cells were covered with a DAPI/methanol solution 
containing 1 µg/ml DAPI (Roche, Mannheim, Germany) 
and incubated for 5 min at room temperature. The cells 
were rinsed with methanol, air dried and mounted onto 
slides with ProLong Gold Antifade (Invitrogen) mount-
ing medium.
Real‑time quantitative PCR analysis
Relative expression analysis for SLC10A4/Slc10a4 was 
performed with ABI PRISM 7300 technology (Applied 
Biosystems, Darmstadt, Germany). RNA was isolated 
from human SH-SY5Y and mouse CAD cells with TriRea-
gent (Sigma-Aldrich) and cDNA was reverse-transcribed 
using the SuperScript III First Strand Synthesis Sys-
tem (Invitrogen). PCR amplification was achieved with 
the TaqMan Gene Expression Assays Hs00293728 for 
human SLC10A4 and Mm00557788 for mouse Slc10a4 
(Applied Biosystems). The expression data of human 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 
Hs99999905) and mouse beta-actin (Mm00607939) were 
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used as an endogenous control. Triplicate determina-
tions were performed in a 96-well optical plate for each 
target, using 5  µl cDNA, 1.25  µl TaqMan Gene Expres-
sion Assay, 12.5  µl TaqMan Universal PCR Master Mix 
(Applied Biosystems) and 6.25  µl water in each 25  µl 
reaction. The plates were heated for 10 min at 95°C, and 
40 cycles of 15 s at 95°C and 60 s at 60°C were applied. 
The relative expression (ΔCT) of each target was calcu-
lated by subtracting the signal threshold cycle (CT) of the 
endogenous control from the CT value of the target.
Western blot analysis
Protein contents of CAD cell lysates were determined 
with the BCA Protein Assay Kit (Novagen, Darmstadt, 
Germany). Samples of 20  µg protein were mixed with 
Laemmli Sample Buffer (Sigma-Aldrich), separated 
on a 12% SDS polyacrylamide gel and transferred to a 
Hybond-ECL nitrocellulose membrane (Amersham Bio-
sciences, Freiburg, Germany). The blotted membranes 
were blocked with blocking solution containing 5% 
ECL-blocking agent (Amersham Biosciences) in TBS-T 
(137  mM NaCl, 10  mM Tris, pH 8.0, 0.05% Tween-20), 
followed by overnight exposure to antigen-specific pri-
mary antibodies at 4°C in the same buffer. After several 
washing steps in TBS-T, the membranes were probed 
with the appropriate horseradish-peroxidase-labeled 
secondary antibodies in TBS-T for 60 min at room tem-
perature. Signals were developed using the Roti-Lumin 
ECL Detection Kit (Roth) and visualized by exposure to 
Hyperfilm ECL (Amersham Biosciences).
Cloning of the reference carriers
Full length transcripts covering the whole open reading 
frame for human SLC10A4, DAT, CHT1, SERT, VMAT2, 
VAChT, NTCP, and mouse Oct1 were amplified by PCR 
with the primers listed in Table  3. All amplicons were 
sequence-verified by DNA sequencing according to 
the GenBank Accession Nos. given in Table 3 and were 
cloned into the pcDNA5/FRT/V5-His TOPO vector (Life 
Technologies) via T/A cloning.
Generation of the SLC10A4/NTCP chimeras
For generation of the SLC10A4/NTCP chimeric con-
structs, the full-length SLC10A4-cDNA5 and NTCP-
pcDNA5 clones with C-terminal V5-tag were used. BmtI 
and HindIII restriction sites were introduced in the N-ter-
mini (amino acid positions A6 in the NTCP and A78 in 
the SLC10A4) and C-termini (amino acid positions E296 
in the NTCP and E374 in the SLC10A4), respectively, 
by site-directed mutagenesis, as previously described in 
detail [8]. Then, by double digestion and re-ligation of the 
appropriate fragments, the following chimeric constructs 
were generated and sequence-verified by direct DNA 
sequencing: SLC10A4-CtNTCP, NtNTCP-SLC10A4-
CtNTCP, NtSLC10A4-NTCP, NtSLC10A4-NTCP-
CtSLC10A4, and NTCP-CtSLC10A4. For generation of 
the N-terminally truncated 75ΔSLC10A4 construct, the 
SLC10A4 open reading frame starting from amino acid 
75 was PCR-amplified and cloned, whereby the codon for 
Gly75 was replaced by an artificial start codon ATG.
Transfection of HEK293 and CAD cells
HEK293 cells were grown in DMEM supplemented with 
10% FCS, 4  mM glutamine and 1% P/S. HEK293 and 
CAD cells were grown at 37°C in 5% CO2. For transient 
transfection, both cell lines were seeded in 24-well plates 
at a density of 1.4–2.0 × 105 cells per well and transfec-
tion was performed by using the Lipofectamine 2000 
reagent according to the manufacturer’s instructions 
(Invitrogen). For the establishment of stably transfected 
Table 3 Primers used for full-length carrier cloning
Carrier Forward primer Reverse primer GenBank Accession Nos.
Human SLC10A1 (Na+/taurocholate co-
transporting polypeptide, NTCP)
5′-tct cta gag gat gga ggc cca caa c-3′ 5′-ggc tgt gca agg gga gca gtc-3′ [GenBank:NM_003049]
Human SLC10A4 5′-acc gac ggg cag aac gac-3′ 5′-gag aga agt ctg agc ggt ttc-3′ [GenBank:NM_152679]
Human SLC6A3 (dopamine transporter, 
DAT)
5′-ctc cca gtg tgc cca tga gta aga g-3′ 5′-cac ctt gag cca gtg gcg gag-3′ [GenBank:NM_001044]
Human SLC5A7 (choline transporter, 
CHT1)
5′-aaa aat ggc ttt cca tgt gga agg-3′ 5′-ctg taa att atc ttc agt ccc ag-3′ [GenBank:NM_021815]
Human SLC6A4 (serotonin transporter, 
SERT)
5′-agg atg gag acg acg ccc ttg aat tc-3′ 5′-cac agc att caa gcg gat gtc ccc a-3′ [GenBank:NM_001045]
Human SLC18A2 (vesicular monoamine 
transporter, VMAT2)
5′-gcc atg gcc ctg agc gag ctg-3′ 5′-gtc act ttc aga ttc ttc atc ttc acc tat 
c-3′
[GenBank:NM_003054]
Human SLC18A3 (vesicular acetylcho-
line transporter, VAChT)
5′-cgg aag agc atc ggg gtg-3′ 5′-gct gcg ggt gta gta gta g-3′ [GenBank:NM_003055]
Mouse Slc22a1 (organic cation trans-
porter, Oct1)
5′-att tca agc cac cgc agt tc-3′ 5′-ggt atg tgg gga ttt gcc t-3′ [GenBank:NM_009202]
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cells, Flp-In HEK293 cells were used (Invitrogen), as 
described previously [3]. Briefly, Flp-In HEK293 cells 
were seeded in 6-well plates coated with poly-d-lysine at 
a density of 1 × 106 cells per well and grown to 60–80% 
confluence in antibiotic free medium. Then, the cells 
were transfected with 1  µg of the respective pcDNA5/
FRT/V5-His vector construct plus 7 µg of pOG44 vector. 
For the selection of positive clones, hygromycin B was 
used at a concentration of 150 µg/ml.
Transport studies in HEK293 and CAD cells
For transport studies, 24-well plates were coated with 
poly-d-lysine for better attachment of the cells. Stably 
or transiently transfected cells were plated at a density 
of 1.25  ×  105 cells per well and grown under standard 
medium for 48–72  h. Before starting the transport 
experiments, cells were washed three times with PBS and 
pre-incubated with sodium transport buffer (142.9  mM 
NaCl, 4.7  mM KCl, 1.2  mM MgSO4, 1.2  mM KH2PO4, 
1.8 mM CaCl2, and 20 mM HEPES, adjusted to pH 7.4). 
When transport assays were performed in sodium-free 
transport buffer, sodium chloride was substituted with 
equimolar concentrations of choline chloride and for the 
transport assay with the substrate [3H]choline chloride 
it was substituted with equimolar concentrations of lith-
ium chloride. For transport studies with [3H]serotonin, 
the uptake buffer contained 100  µM ascorbic acid and 
100 µM pargyline, to prevent the degradation of seroto-
nin. Transport studies were performed by incubating the 
cells with 250 µl transport buffer containing the radiola-
beled and non-radiolabeled compounds for the indicated 
time at 37°C. CAD cells could not be washed before start-
ing the transport experiments because these cells easily 
detached after repeated handling. Therefore, these cells 
were incubated in 250 µl fresh medium plus 50 µl trans-
port buffer containing the radiolabeled and non-radi-
olabeled compounds. Uptake studies were stopped by 
removing the transport buffer and washing the cells five 
times with ice-cold PBS. Afterwards, cells were lysed in 
1 N NaOH with 0.1% SDS and the cell-associated radio-
activity was measured by liquid scintillation counting. 
The protein content was determined using aliquots of the 
lysed cells with BSA as the standard [30].
Transport studies in permeabilized HEK293 cells
Stably transfected HEK293 cells expressing SLC10A4, 
VMAT2 or VAChT were seeded in 24-well plates and 
were grown until confluence. Then, cells were rinsed 
three times with potassium-rich buffer (PB) contain-
ing 110  mM potassium tartrate, 5  mM glucose, 0.2% 
bovine serum albumin, 200  µM CaCl2, 1  mM ascorbic 
acid, 10 µM pargyline and 20 mM piperazine-N,N′-bis(2-
ethanesulfonic acid) (PIPES), adjusted to pH 6.8. The 
cells were permeabilized with 15 µM digitonin in PB for 
15 min at 37°C, as reported [23]. The buffer was replaced 
by 250 µl of PB containing the radiolabeled and non-radi-
olabeled compounds. After incubation for the indicated 
time at 37°C, the uptake was stopped, as described above.
Transport studies in Xenopus laevis oocytes
The pcDNA5/FRT/V5-His constructs containing the 
cloned cDNAs were linearized with KpnI. After phenol/
chloroform extraction, the mMESSAGEmMACHINE 
Kit (Ambion, Life Technologies) was used to generate a 
capped cRNA and the Poly(A) Tailing Kit (Ambion, Life 
Technologies) was used to add a poly(A) tail to the RNA 
transcripts. Afterwards, the cRNA was purified with the 
MEGAclear Kit (Ambion, Life Technologies) according 
to the manufacturer’s protocol. Oocytes were obtained 
from female X. laevis frogs and incubated in Ca2+-free 
OR-2 solution (82.5 mM NaCl, 5 mM HEPES–NaOH, pH 
7.6, 2.5 mM KCl, 1 mM MgCl2 and 1 mM Na2HPO4) sup-
plemented with 0.4 mg/ml collagenase type D (Serva) at 
18°C overnight. Then, oocytes were further incubated in 
modified Barth’s solution (88 mM NaCl, 15 mM HEPES–
NaOH, pH 7.6, 2.4 mM NaHCO3, 1 mM KCl, 0.3 mM Ca 
(NO3)2, 0.41 mM CaCl2 and 0.82 mM MgSO4) containing 
50 µg/ml gentamicin. Defolliculated oocytes were selected 
and microinjected with 4.6 ng (46 nl) cRNA encoding for 
the carrier protein or with a corresponding volume of 
water. After 3 days of culture in modified Barth’s medium, 
uptake of the indicated radiolabelled substrates was 
assessed at 25°C in transport buffer containing 100  mM 
NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 10 mM 
HEPES-Tris, pH 7.5. After washing with the same buffer, 
each individual oocyte was dissolved in 500  µl of 10% 
SDS. The radioactivity was counted after the addition of 
4 ml scintillation fluid in a liquid scintillation counter.
Statistics
Columns are shown as mean  ±  SD. Prism software 
(GraphPad Software Inc., San Diego, CA, USA) was used 
for data presentation and statistical analysis. Statisti-
cal significance of two groups was analyzed by Student’s 
t test. Statistical analysis of more than two groups was 
performed by one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni post hoc testing.
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